TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06810505: A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Sponsor: AbbVie · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 420 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$16,308,416

Rescue Site Savings

+$10,743,720

Unlock Full NCT06810505 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06810505 Rescue Dossier →